Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
Pharma News
FDA warns Jubilant tablet plant in India for repeat mistakes
In one example, the letter said that the facility had received “numerous complaints for damage to functional coating on pantoprazole delayed release tablets” which could affect dissolution.
Long-term exposure to PM2.5 increases risk of diabetes: Chinese study
BEIJING, March 12 (Xinhua) -- A recent study has shown that long-term exposure to PM2.
Pill 'as good as statins' could benefit hundreds of thousands of patients - but it works without the same side effects
A new alternative to statins could help hundreds of thousands of people at risk of heart disease, research suggests.
Merck KGaA, Iktos Enter AI Discovery Partnership
Collaboration gives Merck KGaA access to Iktos AI technology across three drug discovery projects.
EC extends license for Roche/Chugai’s Hemlibra
The European Commission has approved Roche and Chugai Pharma UK’s Hemlibra for the prevention of bleeding episodes in people with severe haemophilia A without factor VIII inhibitors, expanding the d...
Servier & Oncodesign Partner for Parkinson's
Servier and Oncodesign have announced a strategic partnership for the research and development of potential drug candidates for Parkinson's disease.
National Cancer Chief, Ned Sharpless, Named F.D.A.’s Acting Commissioner
WASHINGTON — Dr.
Aerie Pharmaceuticals Announces U.S. FDA Approval of Rocklatan™ (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% for the Reduction of Intraocular Pressure in Patients with Open-Angle Glaucoma or Ocular Hypertension
DURHAM, N.
UK will be ‘less attractive’ for clinical research post Brexit
More than half (52%) of US biotech executives believe that the UK will be a ‘less attractive’ country for conducting clinical trials after Brexit, indicates new research by consultancy...
EMA now operating from Amsterdam Share
Amsterdam relocation As of today, EMA is operating from Amsterdam.
Vedolizumab (Entyvio®) Achieves Superior Rates of Clinical Remission vs. Adalimumab (Humira®) in First Ever Head-to-Head Biologic Clinical Study in Ulcerative Colitis
OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE.
FluroTech Advances Cannabis Biomarker Technology
SEATTLE, March 12, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American canna...
405
406
407
408
409
410
411
412
413
